3,194 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by AE Wealth Management LLC

AE Wealth Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,194 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.

A number of other hedge funds have also recently modified their holdings of GILD. BlackRock Inc. increased its holdings in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after acquiring an additional 1,937,031 shares during the last quarter. Vanguard Group Inc. boosted its stake in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC boosted its stake in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Northern Trust Corp boosted its stake in Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the period. 75.84% of the stock is currently owned by institutional investors.

In related news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the transaction, the chairman now owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. Insiders have sold a total of 578,333 shares of company stock valued at $44,100,508 in the last 90 days. 1.30% of the stock is owned by corporate insiders.

GILD has been the subject of several recent analyst reports. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Finally, ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $86.56.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded up $1.10 during mid-day trading on Friday, hitting $79.32. The company’s stock had a trading volume of 12,694,368 shares, compared to its average volume of 9,910,000. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a market cap of $103,590.00, a P/E ratio of 22.79, a P/E/G ratio of -1.75 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. Gilead Sciences’s revenue was down 18.7% on a year-over-year basis. During the same quarter last year, the company earned $2.70 EPS. equities analysts expect that Gilead Sciences, Inc. will post 6.41 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.87%. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.

TRADEMARK VIOLATION NOTICE: “3,194 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by AE Wealth Management LLC” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/02/11/3194-shares-in-gilead-sciences-inc-gild-acquired-by-ae-wealth-management-llc.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply